Drugs Made In America Acquisition Corp. Units
Drugs Made In America Acquisition Corp. Units
Your view on DMAAU
Overview
What the company does, where it operates, and who runs it.
About Drugs Made In America Acquisition Corp. Units
- Industry
- Shell Companies
- Sector
- Financial Services
- CEO
- Roger Bendelac
- Headquarters
- 420 Lexington Avenue, New York, NY, US
- Industry
- Shell Companies
- Sector
- Financial Services
- CEO
- Roger Bendelac
- Headquarters
- 420 Lexington Avenue, New York, NY, US
Drugs Made In America Acquisition Corp. operates as a special purpose acquisition company (SPAC). Its primary objective is to achieve a business combination, which may involve a merger, an asset acquisition, a share exchange, or a corporate restructuring, with one or more existing enterprises.
The firm was established on May 23, 2024, and maintains its principal office in Fort Lauderdale, Florida.
Stock Data
Price chart, volume, and trading data.
FRC Fair Value Algorithm
What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.
About this section
Fair value for Drugs Made In America Acquisition Corp. Units from FRC's valuation model, read against the market price. DMAAU last traded at $11.39, 55.5× trailing earnings — the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Drugs Made In America Acquisition Corp. Units. Starting points for Drugs Made In America Acquisition Corp. Units: P/E 55.5, EPS $0.30, beta 0.17 — an Shell Companies name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Drugs Made In America Acquisition Corp. Units. Drugs Made In America Acquisition Corp. Units does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Drugs Made In America Acquisition Corp. Units. Trailing twelve-month EPS for Drugs Made In America Acquisition Corp. Units stands at $0.30. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Drugs Made In America Acquisition Corp. Units. Drugs Made In America Acquisition Corp. Units has reported as a listed company since 2025. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
More Shell Companies companies
Market cap
- AFJKAimei Health Technology Co., LtdNASDAQ$39M
- AFJKRAimei Health Technology Co., LtdNASDAQ$625,794
- AFJKUAimei Health Technology Co., Ltd UnitNASDAQ$39M
- AHELFAuscan Resources Inc.OTC$551,565
- AHFDActive Health Foods, Inc.OTC$488
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold Drugs Made In America Acquisition Corp. Units, and how their positions are changing. At a $264.9M market value, institutional positions materially move Drugs Made In America Acquisition Corp. Units's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Drugs Made In America Acquisition Corp. Units executives and directors. Shares of Drugs Made In America Acquisition Corp. Units have traded between $10.30 and $12.50 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Drugs Made In America Acquisition Corp. Units. Coverage tracks Drugs Made In America Acquisition Corp. Units within Shell Companies (Financial Services). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Drugs Made In America Acquisition Corp. Units.